# NCT06394414 (NCT06394414)

> A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06394414
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
- Conditions: Advanced Solid Tumors
- Interventions: YL201
- Enrollment: 187
- Primary outcome: Evaluate the AEs in YL201 combination with serplulimab with or without platinum-based chemotherapy in advanced solid tumors
- Primary outcome: To determine the MTD/RED of YL201 in combination with serplulimab with or without platinum-based chemotherapy in advanced solid tumors
- Primary outcome: To evaluate the efficacy of YL201 in combination with serplulimab with or without platinum-based chemotherapy in advanced solid tumors based on ORR
- Primary outcome: To determine the RP2D of YL201 in combination with serplulimab with or without platinum-based chemotherapy in advanced solid tumors based on ORR

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06394414